Resources

by AstraZeneca

This resource provides information on IMFINZI and how it is used for treatment of several cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), removable stomach (gastric)

by LUNGevity Foundation

This program helps lung cancer patients manage their finances. It includes financial navigation and planning with personalized recommendations for resources that can reduce costs associated with treatment.

by CancerCare

This fact sheet provides an overview of lung cancer and explains how it is treated. It explains how to communicate with your healthcare team, how to stay informed about your cancer, and how to care for

by PAN Foundation

This resource provides financial assistance to non-small cell lung cancer patients who meet the eligibility criteria. It includes a list of medications covered.

by PAN Foundation

This resource provides financial assistance to small cell lung cancer patients who meet the eligibility criteria. It includes a list of medications covered.

by LUNGevity Foundation

This resource discusses accessing financial assistance for biomarker testing, including what to do if concerned about testing costs, if your health insurance denies coverage for testing, and how to access

by Patient Advocate Foundation

This resource provides support for patients with non-small cell lung cancer (NSCLC). It discusses eligibility requirements, which include household income, insurance type, and residency. It helps fund

by Boehringer Ingelheim

This program offers a range of services to help alleviate financial concerns around access. It includes resources and guidance to help patients understand treatment with GILOTRIF, which is used to treat

by Patient Advocate Foundation

This resource provides support for patients with small cell lung cancer (SCLC). It discusses eligibility requirements, which include household income, insurance type, and residency. It helps fund co-pay,

by Patient Advocate Foundation

This resource provides support for patients with non-small cell lung cancer who live in places that need it most (one of the 220+ counties in the US). It discusses eligibility requirements, which include